Recruitment unclearEUCTR 2018-002926-22
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia i...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesEating disorders
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Bulgaria · Hungary and 2 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- 316
- Sponsor
- Helsinn Healthcare SA
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Bulgaria, Hungary, Italy, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2018-002926-22
- Official title
Show the full official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia i...
Recruitment & locations
Status unknownBulgaria · Hungary · Italy
1 more locations
- Romania
Registry details
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Helsinn Healthcare SA.
